Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com. 

Double Bond is a pharmaceutical company which develops and commercializes innovative first-in-class approaches for treatment of cancers, infections, autoimmune diseases and other life-threatening disorders.

a company duly incorporated and organized under the laws of Sweden, having its registered address at Medicon Village, Scheelevagen 2, SE-223 81 Lund, Sweden (“CLS”); CLS is engaged in the research and development of minimally invasive methods for cancer treatment and manufactures the products